Prise en charge des toxicités des thérapies moléculaires ciblées en cancérologie thoracique

S. Rajpar; A. Osio; B. Besse

doi:10.1016/j.pneumo.2008.04.006

Prise en charge des toxicités des thérapies moléculaires ciblées en cancérologie thoracique

S. Rajpar, A. Osio, B. Besse

Résultats de recherche: Contribution à un journal › Article 'review' › Revue par des pairs

1 Citation (Scopus)

Résumé

Targeted molecular therapies, mainly enzyme inhibitors and humanized antibodies, are being widely developed, especially in the area of lung cancer. Though often considered to be better tolerated than conventional cytotoxic chemotherapies, targeted molecular therapies induce specific toxicities that may have detrimental effects on the quality of life. We sum up various toxicities from targeted treatment available for lung cancer in France with the aim of improving their prevention, diagnosis and management.

Titre traduit de la contribution	Management of targeted molecular therapies toxicities in thoracic cancerology
langue originale	Français
Pages (de - à)	104-110
Nombre de pages	7
journal	Revue de Pneumologie Clinique
Volume	64
Numéro de publication	2
Les DOIs	https://doi.org/10.1016/j.pneumo.2008.04.006
état	Publié - 1 avr. 2008

mots-clés

Bevacizumab
Erlotinib
Lung cancer
Targeted molecular therapies
Toxicity

Accès au document

10.1016/j.pneumo.2008.04.006

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{91254466db254c6dadfdc7746acfc00a,

title = "Prise en charge des toxicit{\'e}s des th{\'e}rapies mol{\'e}culaires cibl{\'e}es en canc{\'e}rologie thoracique",

abstract = "Targeted molecular therapies, mainly enzyme inhibitors and humanized antibodies, are being widely developed, especially in the area of lung cancer. Though often considered to be better tolerated than conventional cytotoxic chemotherapies, targeted molecular therapies induce specific toxicities that may have detrimental effects on the quality of life. We sum up various toxicities from targeted treatment available for lung cancer in France with the aim of improving their prevention, diagnosis and management.",

keywords = "Bevacizumab, Erlotinib, Lung cancer, Targeted molecular therapies, Toxicity",

author = "S. Rajpar and A. Osio and B. Besse",

year = "2008",

month = apr,

day = "1",

doi = "10.1016/j.pneumo.2008.04.006",

language = "Fran{\c c}ais",

volume = "64",

pages = "104--110",

journal = "Revue de Pneumologie Clinique",

issn = "0761-8417",

number = "2",

}

TY - JOUR

T1 - Prise en charge des toxicités des thérapies moléculaires ciblées en cancérologie thoracique

AU - Rajpar, S.

AU - Osio, A.

AU - Besse, B.

PY - 2008/4/1

Y1 - 2008/4/1

N2 - Targeted molecular therapies, mainly enzyme inhibitors and humanized antibodies, are being widely developed, especially in the area of lung cancer. Though often considered to be better tolerated than conventional cytotoxic chemotherapies, targeted molecular therapies induce specific toxicities that may have detrimental effects on the quality of life. We sum up various toxicities from targeted treatment available for lung cancer in France with the aim of improving their prevention, diagnosis and management.

AB - Targeted molecular therapies, mainly enzyme inhibitors and humanized antibodies, are being widely developed, especially in the area of lung cancer. Though often considered to be better tolerated than conventional cytotoxic chemotherapies, targeted molecular therapies induce specific toxicities that may have detrimental effects on the quality of life. We sum up various toxicities from targeted treatment available for lung cancer in France with the aim of improving their prevention, diagnosis and management.

KW - Bevacizumab

KW - Erlotinib

KW - Lung cancer

KW - Targeted molecular therapies

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=68649125581&partnerID=8YFLogxK

U2 - 10.1016/j.pneumo.2008.04.006

DO - 10.1016/j.pneumo.2008.04.006

M3 - Article 'review'

C2 - 18589292

AN - SCOPUS:68649125581

SN - 0761-8417

VL - 64

SP - 104

EP - 110

JO - Revue de Pneumologie Clinique

JF - Revue de Pneumologie Clinique

IS - 2

ER -